menu
    • menu
    [{"orgOrder":0,"company":"Carlsbad Technology","sponsor":"Tyra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carlsbad Technology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Carlsbad Technology \/ Carlsbad Technology","highestDevelopmentStatusID":"7","companyTruncated":"Carlsbad Technology \/ Carlsbad Technology"}]

    Find Clinical Drug Pipeline Developments & Deals by Carlsbad Technology

    Menu

    Carlsbad Technology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Carlsbad Technology

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Carlsbad Technology

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TYRA-300

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Tyra Biosciences

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Tyra Biosciences Wants to Bank $100 M for an IPO

                            Details : TYRA-300, a selective inhibitor of FGFR3, for the treatment of FGFR3-driven cancers initially for patients with bladder cancer who are resistant to FGFR therapies. TYRA-300 has demonstrated potency against both wild-type and resistant FGFR3 targets.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 20, 2021

                            Lead Product(s) : TYRA-300

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Tyra Biosciences

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth